中国医药(600056) - 2022 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2022 was ¥8,519,901,885.91, representing a year-on-year decrease of 0.61%[2] - Net profit attributable to shareholders for Q1 2022 was ¥245,980,075.89, showing a year-on-year increase of 15.51%[2] - The net profit after deducting non-recurring gains and losses was ¥216,078,999.08, with a growth of 15.73% compared to the previous year[2] - Total operating revenue for Q1 2022 was CNY 8,519,901,885.91, a slight decrease of 0.6% compared to CNY 8,571,905,223.52 in Q1 2021[14] - Total operating costs for Q1 2022 were CNY 8,171,489,314.14, down 0.8% from CNY 8,237,220,801.25 in Q1 2021[14] - Net profit for Q1 2022 reached CNY 300,838,706.54, representing an increase of 11.9% from CNY 268,923,247.05 in Q1 2021[15] - Basic earnings per share for Q1 2022 were CNY 0.2302, up from CNY 0.1993 in Q1 2021[16] - Total comprehensive income for Q1 2022 was CNY 300,838,706.54, compared to CNY 268,923,247.05 in Q1 2021[15] Assets and Liabilities - The total assets at the end of Q1 2022 reached ¥32,312,430,711.92, an increase of 3.86% from the end of the previous year[3] - The total current assets as of March 31, 2022, amounted to RMB 23,548,061,912.53, an increase from RMB 22,189,094,818.06 as of December 31, 2021, representing a growth of approximately 6.13%[9] - Accounts receivable reached RMB 12,376,372,521.28, up from RMB 11,165,822,791.05, indicating an increase of about 10.84% year-over-year[9] - The total liabilities increased to RMB 19,500,567,583.48 from RMB 18,601,090,827.83, marking an increase of about 4.83%[12] - The company's cash and cash equivalents were reported at RMB 2,377,434,617.18, down from RMB 2,798,930,977.04, a decrease of approximately 15.06%[9] - Inventory levels stood at RMB 5,884,339,358.14, showing a slight increase from RMB 5,656,741,303.37, which is an increase of about 4.02%[11] - The company's long-term borrowings rose to RMB 3,552,000,000.00 from RMB 2,982,000,000.00, representing an increase of approximately 19.14%[12] - The company's short-term borrowings decreased to RMB 1,284,206,072.30 from RMB 1,490,256,072.30, a reduction of approximately 13.83%[12] - The contract liabilities decreased to RMB 1,245,893,380.75 from RMB 1,389,282,312.97, reflecting a decline of about 10.34%[12] Cash Flow - The net cash flow from operating activities was negative at -¥901,941,859.28, indicating challenges in cash generation[2] - Cash flow from operating activities for Q1 2022 was negative CNY 901,941,859.28, compared to negative CNY 588,255,884.34 in Q1 2021[17] - Cash inflow from operating activities totaled CNY 8,071,088,677.49, an increase from CNY 7,967,296,626.57 in Q1 2021[17] - Cash outflow from operating activities was CNY 8,973,030,536.77, compared to CNY 8,555,552,510.91 in Q1 2021[17] - The net cash flow from investing activities was $170,031,021.73, a significant improvement from a negative cash flow of $43,233,791.99 in the same quarter of 2021[18] - Cash inflow from financing activities totaled $1,305,000,000.00, compared to $1,162,000,000.00 in Q1 2021, indicating a year-over-year increase of approximately 12.3%[18] - The net cash flow from financing activities was $318,964,182.28, a turnaround from a negative cash flow of $634,442,584.68 in the previous year[18] - The total cash and cash equivalents at the end of the period stood at $1,421,560,610.25, slightly up from $1,407,524,388.39 in Q1 2021[18] - The company reported a cash outflow of $986,035,817.72 from financing activities, down from $1,796,442,584.68 in the same quarter last year, reflecting a reduction of approximately 45%[18] - The cash outflow for the acquisition of fixed assets, intangible assets, and other long-term assets was $30,648,017.10, down from $66,079,746.62 in Q1 2021[18] - The company experienced a foreign exchange impact of $193,376.67 on cash and cash equivalents, compared to a negative impact of $134,699.15 in the previous year[18] - The total cash inflow from investment activities was $209,727,480.02, a significant increase from $23,070,914.24 in Q1 2021[18] - The company reported a cash outflow of $39,696,458.29 from investment activities, a decrease from $66,304,706.23 in the same quarter of the previous year[18] - The company’s initial cash and cash equivalents balance was $1,834,313,888.85, compared to $2,673,591,348.55 at the beginning of Q1 2021[18] Research and Development - Research and development expenses increased by 42.06% during the reporting period[5] - Research and development expenses for Q1 2022 were CNY 14,696,949.23, up from CNY 10,345,643.17 in Q1 2021[14] Investment Income - Investment income surged by 99.27%, attributed to increased returns from joint ventures[5] - Investment income from joint ventures and associates was CNY 6,471,900.00, compared to CNY 2,711,346.62 in Q1 2021[14] - The weighted average return on equity rose by 0.26 percentage points to 2.37%[2]